Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
national blog main
texas blog main
103
×
texas top stories
national top stories
life sciences
boston blog main
san diego blog main
new york blog main
raleigh-durham blog main
san francisco blog main
wisconsin blog main
detroit blog main
seattle blog main
boulder/denver blog main
san diego top stories
san francisco top stories
wisconsin top stories
national
new york top stories
raleigh-durham top stories
seattle top stories
biotech
boston top stories
detroit top stories
indiana blog main
boulder/denver top stories
indiana top stories
fda
startups
texas
venture capital
medical devices
cancer
clinical trials
funding
medical device
san antonio
innovation
merck
pfizer
What
roundup
bio
drug
medical
san
news
new
texas
antonio
innovation
latest
cancer
tx
tech
let’s
life
based
fda
medicine
week
company
drugs
catch
companies
million
science
startup
ipo
plan
raised
sciences
conference
healthcare
known
announced
annual
austin
caught
health
moves
Language
unset
unknown
Current search:
" texas blog main "
×
@xconomy.com
3 months ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 months ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 months ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
4 months ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 months ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
9 months ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
10 months ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
11 months ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
11 months ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
11 months ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
1 year ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
1 year ago
Bio Roundup: Nobel Prizes, Placebo Effect Rises, ICER’s Fire & More
@xconomy.com
1 year ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com
1 year ago
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
@xconomy.com
1 year ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
1 year ago
Pelosi, Dems Unveil Price Plan: Are 25 Drugs Enough for Negotiation?
@xconomy.com
1 year ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com
1 year ago
After First Look at House Drug Plan, Stocks Rise Slightly
@xconomy.com
1 year ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
1 year ago
Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More
@xconomy.com
1 year ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
@xconomy.com
1 year ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
1 year ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
1 year ago
White House Floats Canadian Import Plan But Excludes Many Costly Drugs
@xconomy.com
1 year ago
San Antonio to Honor Regenerative Medicine Pioneer Stephen Badylak
@xconomy.com
1 year ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
1 year ago
New Funds for Procyrion, Remedy, OncoNano, Vyopta & More TX Tech
@xconomy.com
1 year ago
Review: Inside the House of Lies at Theranos
@xconomy.com
1 year ago
From Farm to (Financial) Table: Holt Ventures Partner Meg Paulus
@xconomy.com
1 year ago
Can Tiny Drug Doses (and One Woman’s Fortune) Fight the Most Vicious Cancer?
@xconomy.com
1 year ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com
1 year ago
MedCognition Making Augmented Reality Emergency Training for US Army
@xconomy.com
1 year ago
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More
@xconomy.com
1 year ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
1 year ago
Acelity Sells to 3M in Deal Valued at $6.7 Billion, Ending IPO Plan
@xconomy.com
1 year ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
1 year ago
San Antonio Wound-Care Company Eyes (Another) Initial Public Offering
@xconomy.com
1 year ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
1 year ago
UT Health San Antonio Plans New Accelerator for Faculty Research
@xconomy.com
1 year ago
Chevron Tech, Medical Informatics, ActivTrak, Linear & More TX Tech
@xconomy.com
1 year ago
Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More
@xconomy.com
1 year ago
AgileCraft’s Exit, $45M for Ojo Labs, Intel Grants & More TX Tech
@xconomy.com
1 year ago
Bio Roundup: Sage Postpartum Help, Biogen Bids Adu, Heart Beats & More
@xconomy.com
1 year ago
JLabs’ Luby Takes the Reins at TMC Innovation Institute in Houston
@xconomy.com
1 year ago
Pharma CEOs to Senate: We Will Lower Drug Prices if Rebates Go Away
@xconomy.com
1 year ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
1 year ago
GenCure Plans Adult Stem Cell Lab at San Antonio “Innovation Center”
@xconomy.com
1 year ago
Bio Roundup: Trump’s Scalps, Policy Pressure, NASH Crash & More
First
Prev
Page 1
(current)
Next
Last